TABLE 2.
Baseline characteristics of HT and non-HT patients in enrolled cases.
| Clinical information | Non-HT (n = 32) | HT (n = 5) | p value |
| Age (year) | 63.81 ± 9.036 | 70.2 ± 7.328 | 0.143 |
| Male (%) | 84.4 | 80 | 0.805 |
| Median NIHSS score (IQR) | 2.5 (1–4.75) | 11 (4.5–20) | 0.006 |
| Median mRS score (IQR) | 2 (2–2.75) | 2 (1–3.5) | 0.605 |
| Atrial fibrillation (no. %) | 4 (12.5) | 2 (40) | 0.121 |
| Diabetes (no. %) | 6 (18) | 1 (20) | 0.947 |
| Hypertension (no. %) | 18 (56.3) | 5 (100) | 0.061 |
| History of antiplatelets treatment (no.%) | 10 (31.25%) | 2 (40%) | 0.698 |
| History of anticoagulants treatment (no. %) | 1 (3%) | 1 (20%) | 0.625 |
| Median time from Onset to Door (h. IQR) | 4 (2.125–12) | 4.5 (2–11) | 0.541 |
| Median time from onset to sample (h. IQR) | 4.35 (2.3–12.05) | 4.6 (2.2–11.2) | 0.794 |
| Median time from onset to the first imaging (CT, h. IQR) | 4.46 (2.425–12.15) | 4.65 (2.275–11.275) | 0.780 |
| Median time from onset to second imaging (MRI, h, IQR) | 45.2 (43.625–48.3) | 43.5 (41.5–45.5) | 0.176 |
| Median time from onset to third imaging (CT, h, IQR) | 143.5(135–149) | 147.55(139.975–153.175) | 0.237 |
| Fibrinogen (g/L) | 3.73 ± 1.075 | 4.53 ± 1.243 | 0.491 |
| Platelet (109/L) | 37.02 ± 4.678 | 36.86 ± 4.381 | 0.702 |
| Activated partial thromboplastin time (s) | 204.63 ± 47.375 | 232.4 ± 117.594 | 0.628 |
| International normalized ratio | 1.05 ± 0.09 | 1.12 ± 0.08 | 0.115 |
| Antiplatelet therapies within 48 h (no.%) | 0.355 | ||
| Single antiplatelet therapy | 2 (6.3%) | 1 (20%) | |
| Dual antiplatelet therapy | 30 (93.8%) | 4 (80%) |